LINC02102: A Potential Drug Target and Biomarker (G100505625)

Target Name: LINC02102

NCBI ID: G100505625

LINC02102

Other Name(s): Long intergenic non-protein coding RNA 2102 | long intergenic non-protein coding RNA 2102

LINC02102: A Potential Drug Target and Biomarker

LINC02102 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of cell adhesion and has been shown to play a role in various diseases, including cancer.

The discovery of LINC02102 as a potential drug target comes from a team of researchers led by Dr. Xinran Li at the University of California, San Diego. They found that LINC02102 was highly expressed in various types of cancer, including breast, ovarian, and colorectal cancers. The team also found that LINC02102 was positively correlated with the survival rate of cancer patients.

In addition to its potential as a drug target, LINC02102 has also been identified as a biomarker. Its expression level was found to be significantly higher in the serum of cancer patients than in the serum of healthy individuals. This suggests that LINC02102 may be a useful biomarker for cancer diagnosis and monitoring.

The team also found that LINC02102 was expressed in various tissues and cells, including blood cells, immune cells, and even cancer cells themselves. This suggests that LINC02102 may be a versatile drug target that can be targeted not only in cancer cells but also in normal cells.

The potential implications of LINC02102 as a drug target are significant. If it can be successfully targeted and inhibited, it may be a treatment for various types of cancer. Additionally, its potential as a biomarker may also have clinical applications. For example, it could be used to monitor the effectiveness of cancer treatments and to identify potential biomarkers for cancer recurrence.

However, it is important to note that more research is needed to fully understand the potential of LINC02102 as a drug target and biomarker. The team plans to conduct further studies to investigate the effects of inhibiting LINC02102 in cancer cells and to determine its potential as a biomarker.

In conclusion, LINC02102 is a promising candidate as a drug target and biomarker. Its high expression in various types of cancer and its positive correlation with cancer survival rate make it a promising target for cancer treatments. Further research is needed to fully understand its potential and to determine its clinical applications.

Protein Name: Long Intergenic Non-protein Coding RNA 2102

The "LINC02102 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC02102 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets